Peptide Therapeutics Market – Innovation Expands Opportunities in Metabolic Care and Oncology

The peptide therapeutics market is expanding as pharmaceutical companies develop targeted therapies for metabolic disorders, oncology, endocrine conditions, autoimmune diseases, and other complex illnesses. The market reached USD 43.80 billion in 2025 and is projected to grow to USD 83.80 billion by 2035, at a CAGR of 6.7%.marketresearchfuture

Peptide medicines are increasingly important because they can be designed to interact with specific biological pathways. Their use is well established in areas such as metabolic care, endocrine disorders, oncology, and rare diseases. Recent commercial success in incretin-class therapies has also increased investment in peptide-based drug discovery and manufacturing.

Oncology is the largest application segment, contributing approximately 38.2% of market revenue in 2025. This position is supported by peptide-drug conjugates, radioligand therapies, somatostatin analogs, and targeted treatment approaches. Metabolic disease is another major area, particularly as GLP-1 and multi-agonist therapies reshape diabetes and obesity care.

Parenteral administration remains dominant, accounting for around 75% of 2025 volume. Injectables remain important because many peptide molecules require delivery routes that protect their therapeutic activity. Oral peptide formulations are expected to grow more quickly as permeation enhancers, enteric coatings, and formulation technologies improve.

Solid-phase peptide synthesis is the leading production technology, while recombinant expression is expected to grow rapidly for more complex and longer peptide sequences. Manufacturing innovation is focused on reducing cost, increasing scale, improving consistency, and supporting global supply.

North America accounts for approximately 41% of the market, while Asia-Pacific is projected to grow fastest. Major companies include Novo Nordisk, Eli Lilly, Sanofi, AstraZeneca, Takeda Pharmaceutical, Ipsen, Teva Pharmaceutical, Bachem Holding, Amgen, and Sun Pharmaceutical Industries.marketresearchfuture

Read more: Peptide Therapeutics Market

People Also Ask

Q1. What are peptide therapeutics?
They are medicines based on short chains of amino acids designed to target specific biological pathways.

Q2. Which therapeutic area leads the peptide therapeutics market?
Oncology leads, supported by peptide-drug conjugates, radioligand therapies, and targeted treatment approaches.

Tags: peptide therapeutics, oncology peptides, metabolic disease treatment, peptide drug development, targeted therapies